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Objective. To perform a systematic review and meta-analysis on studies that assess malignant transformation rates (MTR) of oral
epithelial dysplasia. Materials and Methods. This review was planned and conducted in accordance with the meta-analysis of
observational studies in epidemiology (MOOSE) guidelines. PubMed, EMBASE, Google Scholar, and Cochrane databases were
screened to identify observational studies. Quality assessments were completed by two reviewers independently using the Quality
Assessment Tool for Observational Cohort and Cross-Sectional Studies. Pooled-malignant transformation rate (MTR) in person
years, subgroup, sensitivity, and publication bias analysis were calculated using STATA 13.0 and Comprehensive Meta-Analysis
software. Results. Sixteen observational cohort studies were identified with a total of 3708 participants from Asia, North America,
and Europe. Analysis showed aMTR of 10.5% (pooled-MTR: 10.5, 95%CI: 3.7 to 17.3; fixed effect model, 𝐼2 = 0.0%;𝑄-value = 2.389;
𝑝 > 0.05) among patients with histologically confirmed oral epithelia dysplasia undergoing long-term follow-up. Higher MTR in
person year were seen among the sever dysplastic cases (pooled-MTR: 14.4%, 95% CI: 5.3% to 23.5%), studies published in Europe
(pooled-MTR: 12.6%, 95% CI: 8.0% to 24.3%), and retrospective studies (pooled-MTR: 11.0%, 95% CI: 2.2% to 19.9%). Conclusion.
These studies show that oral epithelial dysplasia has a significant high rate of transformation to cancer.
1. Introduction
Oral cancer is a potentially fatal disease that affects the oral
cavity (themouth) or the oropharynx (the part of the throat at
the back of the mouth) [1]. Oral cavity cancer is amongst the
most prevalent cancers worldwide [1]. In the United States,
approximately 42,440 people are expected to be diagnosed
with oral cancer in 2014, among which 8390 will not be alive
in five years [2]. In fact, it has also been classified as the
sixth most frequent leading cause of cancer death worldwide.
Though the oral cavity is accessible for direct examination,
these malignancies are still detected at a late stage. Death
rates due to oral cancer are particularly high not because
it is hard to discover or diagnose, but because oral cancer
in its early stage can be painless and go unnoticed in its
development [2].
Oral epithelial dysplasia (OED) on the other hand is
a potentially malignant lesion of the oral mucosa with an
unpredictable course of progression [3], where there is expan-
sion of immature cells (such as cells of the ectoderm), with a
corresponding decrease in the number and location ofmature
cells [3]. The presence of epithelial dysplasia is generally
regarded as one of the most vital predictors of malignant
transformation [4]. The early and careful diagnosis is of
extreme significance, which allows arresting the progression
of oral epithelial dysplasia to oral squamous cell carcinoma.
Therefore, it is important to understand the rate and duration
of malignant transformation in these precancerous oral
lesions so as to make them more amenable to treatment with
the greatest chance of cure.
The primary objective of this systematic review andmeta-
analysis is to assess the progression of oral epithelial dysplasia
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to cancer by examining observational cohort studies for
outcome measure which include malignant transformation
rate (MTR). The secondary objective is to examine the
difference in theMTRmeasure based on the level of dysplasia.
2. Methods
2.1. Protocol and Registration. This review was planned and
conducted in accordance with the meta-analysis of observa-
tional studies in epidemiology (MOOSE) guidelines [5]. The
protocol was not registered on any database.
2.2. Eligibility Criteria. To be considered for review, studies
had to meet the following criteria:
(i) Type of studies: observational cohort studies (pro-
spective and retrospective) evaluating the progression
(MTR) of oral epithelial dysplasia to oral cancer were
included.
(ii) Study participants: histologically confirmed oral
epithelial dysplasia participants were included. Stud-
ies reporting on oral leukoplakia patients as dysplasia
were excluded.
(iii) Outcome and outcomemeasure: the rate ofmalignant
transformation (MTR) in person years of oral epithe-
lial dysplasia to oral cancer was included.
(iv) Length of follow-up: only studies with a minimum
follow-up time of 2 years were included.
(v) Reporting of results: studies that reported on MTR
of oral epithelial dysplasia or reported on incidence
of malignant cases during the follow-up period that
could be used to calculate MTR were included.
(vi) Accessibility of data: studies were eligible only if they
were published as full papers in English language.
2.3. Literature Search. The following electronic databases
were searched between the respective periods: PubMed/Med-
line (1966 to December 2014), Embase (1980 to Decem-
ber 2014), and Cochrane databases (CENTRAL, Cochrane
Library, 1995 to December 2014). The literature search was
constructed around the following search terms: “oral epithe-
lial dysplasia”, “malignant transformation”, and “oral cancer”
whichwere adapted for each database as necessary. For exam-
ple, the following search strategy was used on the PubMed
database: (“Oral” [MeSH] OR “Mouth” [All Fields] AND
(“dysplasia,” [MeSH]) OR (“malignant transformation” [All
Fields]) OR (“cancer” [All Fields] OR “neoplasm” [MeSH])).
The reference lists of identified original articles or reviews
were also searched manually for relevant articles.
2.4. Study Selection. Two independent investigators searched
for articles that meet the aforementioned eligibility criteria.
The two investigators compared search results to ensure com-
pleteness and then reviewed the full title and abstract of the
articles retrieved in the initial literature search. Differences
in eligible studies were reviewed and resolved by mutual
agreement between the 2 reviewers. Duplicate articles and
those not meeting study eligibility criteria were removed.
After removal of all duplicate papers, the reviewers screened
the abstracts of the remaining papers individually. They
went on to obtain the full papers for all potentially eligible
studies, which were then checked for eligibility using the
standard abstraction forms; the eligible papers were included
in the systematic review. To ensure completeness of the
systematic literature review, all of the references in the articles
deemed eligible for inclusion in the study were searched by
investigators for relevant articles.
2.5. Data Collection. Two reviewers independently extracted
data using the standard data abstraction form on studies’
characteristics: study design, length of follow-up, exposure
(OED presence and grade of OED), and time to outcome
measure (MTR to oral cancer). The abstraction form also
includes the title of the paper, authors’ information, country
in which the study was conducted, and population charac-
teristics (mean age, gender). Differences in paper selection
and data abstraction were reviewed and resolved by mutual
agreement between the 2 reviewers.
2.6. Data Analysis. Meta-analysis was conducted on the
collected data from each of the selected observational cohort
studies using STATA 13.0 and Comprehensive Meta-Analysis
software v3.
2.7. Quality Assessment. The quality of the identified studies
was assessed independently by the two reviewers using the
“Quality Assessment Tool for Observational Cohort and
Cross-Sectional Studies,” provided by the National Institute
of Health (NIH) [6], by assessing the potential risk for
selection bias, information bias, measurement bias, or con-
founding (confounding includes cointerventions, differences
at baseline in patient characteristics, and other issues as
shown in Table 3). Studies were rated as good, fair, and poor
quality, where high risk of bias translated to a rating of poor
quality (“−”) and low risk of bias translated to a rating of good
quality (“+”).
2.8. Assessment of Heterogeneity. The degree of dissimilarity
in the results of individual studies or heterogeneity was
assessed graphically using forest plot and the exact bino-
mial confidence intervals (CIs) were calculated. Statistical
heterogeneity between the reviewed studies was quantified
by determination of the DerSimonian and Laird estimate
(𝐼2), where 𝐼2 > 30%, 𝐼2 > 50%, and 𝐼2 > 75% were
defined to indicate moderate, substantial, and considerable
heterogeneity, respectively. Cochran’s𝑄 test is a statistical test
used in conjunction with the forest plot to determine the
significance (𝑝 value ≤ 0.05) of heterogeneity among studies.
2.9. Subgroup and Sensitivity Analyses. Subgroup analyses
were conducted on the identified studies by grouping them
by their study design (prospective or retrospective study), the
region in which they were published (Asia, North America,
and Europe), and the grade of dysplasia (mild, moderate, and
severe).
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Studies identified through database searching
(Medline, EMBASE, CINAHL, and Google Scholars) Duplicate studies excluded
Studies available after removing duplicates Studies excluded after title and abstract review
Studies assessed for eligibility after full-text review Studies excluded by full-text review








Figure 1: Flow chart showing the flow of article selection for meta-analysis.
Sensitivity analyses to test the robustness of any signif-
icant results were conducted by comparing the results of
studies with high risk versus low risk at the domains selection
bias, detection bias, attrition bias, and other risks. Significant
𝑄-statistics (𝑝 value ≤ 0.05) or 𝐼2 statistic greater than 30%
was considered as evidence of significant heterogeneity in the
respective meta-analysis.
2.10. Risk of Bias across the Studies. The risk of publication
bias was assessed by visual analysis of funnel plots generated
by Comprehensive Meta-Analysis v3. Roughly symmetrical
funnel plots will indicate a low risk of publication bias, while
asymmetrical funnel plots indicate a high risk of such bias.
3. Results
3.1. Study Selection. The literature search retrieved 3386
records of which 262 were duplicates. After title and abstract
screening, 3176 records were excluded. Of the remaining 51
articles that were assessed for eligibility by full text review, 7
were cross-sectional studies, 24 did not report our primary
outcome (MTR) and were thus excluded, and 4 reported
on patients with oral leukoplakia without histologically con-
firmed diagnosis of dysplasia and were excluded. At the end,
16 studies with a total of 3708 patients were included in the
qualitative and quantitative analysis (Figure 1).
3.2. Study Characteristics. The characteristics of the study
samples, interventions, outcome measures, and results are
shown in Table 1.
3.2.1. Setting and Participant Characteristics. Studies origi-
nated from all over the world: four from Asia: India [7],
Taiwan [8, 9], and China [10]; six from Europe: Denmark
[11], Northern Ireland [12], Hungary [13], England [14, 15],
and Italy [16]; and six fromNorth America: USA [17–20] and
Canada [21, 22]. Six studies [15, 16, 19–22] had a sample size
greater than 200 participants with the largest population of
1434 patients in one study [21]. Five studies [7, 8, 14, 17, 22]
were prospective hospital based studies, ten [9–11, 13, 15, 16,
18–21] were retrospective hospital based studies, and one was
retrospective laboratory based study [12]. Mean age of the
study population ranged from 46.7 to 63.9 years as reported
in 13 of the 16 studies with a mean follow-up period ranging
from 2.5 to 9.3 years among all the 16 studies (Table 1).
3.2.2. Outcome Measures. Malignant transformation rate
(MTR) was reported or calculated by using the incidence
malignant cases over the total number of dysplastic cases
across all 16 studies.MTRwas also calculated by the histologic
grade of dysplasia: mild, moderate, and severer (Table 2).
3.2.3. Risk of Bias in Individual Studies. No study was con-
sidered to be seriously flawed as per the “Quality Assessment
Tool for Observational Cohort and Cross-Sectional Studies”
[6].
Studies’ risk to performance bias was moderately low
across all the 16 studies, with five studies [11, 12, 14, 20, 22]
having some form of risk due to nonblinding. The risk of
attrition bias due to incomplete outcome data was absent
across all the studies (Table 3).
3.3. Malignant Transformation Rate in
Oral Epithelial Dysplasia
3.3.1. Test for Heterogeneity and Pooled-Malignant Transfor-
mation Rate. All the studies looked at the rate of malignant
transformation among individuals with histologically con-
firmed oral epithelial dysplasia followed over a range of mean
follow-up years of 2.5 to 9.0 years. Using forest plots from
the DerSimonian and Laird (D&L) random effects model
(random effectmodel: pooled-MTR= 10.5%, CI: 3.7 to 17.3%),
two studies were seen to be weighted higher than the others
with no heterogeneity (𝐼2: 0.0%; 𝑄-value = 2.389, 𝑝 > 0.05)
across all the 16 studies. Hence, D&L fixed effects model was
used to estimate the final pooled-malignant transformation
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Table 1: Description of selected studies.




Mean age Sample size
Ba´no´czy [13] 1976 Hungary Europe Retrospective hospital 6.3 NR 68
Mincer [17] 1972 USA North America Prospective hospital 8.0 NR 45
Gupta [7] 1980 India Asia Prospective hospital 8.5 NR 90
Lumerman [18] 1995 USA North America Retrospective hospital 2.5 57.0 43
Cowan [12] 2001 Northern Ireland Europe Retrospective laboratory 4.0 57.7 165
Holmstrup [11] 2006 Denmark Europe Retrospective hospital 6.0 60.8 82
Hsue [8] 2007 Taiwan Asia Prospective hospital 3.6 47.5 166
Ho [9] 2009 Taiwan Asia Retrospective hospital 3.1 46.7 33
Arduino [16] 2009 Italy Europe Retrospective hospital 4.5 63.9 207
Bradley [21] 2010 Canada North America Retrospective hospital 3.7 57.5 1434
Liu [10] 2011 China Asia Retrospective hospital 5.1 52.7 138
Warnakulasuriya [15] 2011 England Europe Retrospective hospital 6.0 56.5 204
Zhang [22] 2012 Canada North America Prospective hospital 3.7 60.8 296
Ho [14] 2012 England Europe Prospective hospital 9.0 48.5 91
Sperandio [19] 2013 USA North America Retrospective hospital 9.3 55.0 201
Dost [20] 2014 USA North America Retrospective hospital 3.3 59.5 368
NR: not reported.
Table 2: Oral epithelial dysplasia (OED) count and malignant transformation rate (MTR).
First author Year Oral epithelial dysplasia Malignant transformation Malignant transformation rate
Total Mild Mod. Sev. Total Mild Mod. Sev. Total Mild Mod. Sev.
Ba´no´czy [13] 1976 68 13 43 12 9 1 3 5 13.2% 7.7% 7.0% 41.7%
Mincer [17] 1972 45 NA 32 13 5 NA 2 3 11.1% NA 6.3% 23.1%
Gupta [7] 1980 90 NA NA NA 6 NA NA NA 6.7% NA NA NA
Lumerman [18] 1995 43 19 18 6 7 3 3 1 16.3% 15.8% 16.7% 16.7%
Cowan [12] 2001 165 NA NA NA 24 NA NA NA 14.6% NA NA NA
Holmstrup [11] 2006 82 42 26 14 8 5 2 1 9.8% 11.9% 7.7% 7.1%
Hsue [8] 2007 166 NA NA NA 8 NA NA NA 4.8% NA NA NA
Ho [9] 2009 33 NA NA NA 8 NA NA NA 24.2% NA NA NA
Arduino [16] 2009 207 135 50 22 15 4 2 9 7.3% 3.0% 4.0% 43.0%
Bradley [21] 2010 1434 959 326 149 139 47 43 49 9.7% 4.9% 13.2% 32.9%
Liu [10] 2011 138 92 NA 46 37 17 NA 20 26.8% 18.5% NA 43.5%
Warnakulasuriya [15] 2011 204 104 70 30 24 5 11 8 11.8% 4.8% 15.7% 26.7%
Ho [14] 2012 91 40 31 20 23 8 11 11 25.3% 20.0% 35.5% 55.0%
Zhang [22] 2012 296 127 135 34 41 16 19 6 13.9% 12.6% 14.1% 17.7%
Sperandio [19] 2013 201 103 69 29 17 4 7 6 8.5% 3.9% 10.1% 20.7%
Dost [20] 2014 368 221 85 55 26 9 6 1 7.1% 4.1% 7.1% 1.8%
NA: not available.
rate over mean follow-up years (fixed effect model: pooled-
MTR: 10.5%, CI: 3.7% to 17.3%) (Figure 2).
3.3.2. Subgroup and Sensitivity Analyses. A subgroup analysis
by study design showed a higher pooled-MTR in person years
among the eleven retrospective studies (pooled-MTR: 11.4%,
CI: 2.2% to 19.9%; fixed effect model: 𝐼2 = 0.0%, 𝑄-value:
1.134, and 𝑝 > 0.05) as compared to the five prospective
studies (pooled-MTR: 9.7%, CI: −0.9% to 20.4%; fixed effect
model: 𝐼2 = 0.0%,𝑄-value: 1.221, and 𝑝 > 0.05) (Figure 3). Six
studies published from Europe were shown to have a higher
pooled-MTR in person years (pooled-MTR: 12.6%, 95% CI:
0.8% to 24.3%; fixed effect model: 𝐼2 = 0.0%, 𝑄-value: 0.815,
and 𝑝 > 0.05) as compared to the six studies from North
America (pooled-MTR: 9.9%, 95% CI: −1.3% to 21.0%; fixed
effect model: 𝐼2 = 0.0%, 𝑄-value: 0.175, and 𝑝 > 0.05) and
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First author (year) MTR SE 95% LCI 95% UCI MTR and 95% CI
0.132 0.145 −0.152 0.416
Mincer et al. (1972) 0.111 0.118 −0.120 0.342
Gupta et al. (1980) 0.057 0.089 −0.107 0.240
Lumerman et al. (1995) 0.163 0.255 −0.337 0.663
Cowan et al. (2001) 0.145 0.191 −0.228 0.519
Holmstrup et al. (2006) 0.098 0.128 −0.152 0.347
Hsue et al. (2007) 0.048 0.115 −0.178 0.274
Ho et al. (2009) 0.242 0.280 −0.306 0.791
Arduino et al. (2009) 0.072 0.127 −0.176 0.321
Bradley et al. (2010) 0.097 0.162 −0.220 0.414
Warnakulasuriya et al. (2011) 0.118 0.152 −0.180 0.415
Liu et al. (2011) 0.268 0.211 −0.146 0.682
Ho et al. (2012) 0.253 0.168 −0.076 0.581
Zhang et al. (2012) 0.139 0.193 −0.241 0.518
Sperandio et al. (2013) 0.085 0.095 −0.102 0.271
Dost et al. (2014) 0.071 0.146 −0.216 0.357
Pooled-MTR 0.105 0.035 0.037 0.173
−0.50 −0.25 0.00 0.25 0.50
B ́anóczy and Csiba (1976)
I2: 0.0%; Q-value: 2.389, df: 15, and p = 1.000.
Figure 2: DerSimonian and Laird fixed effect model: malignant transformation rate (MTR) of dysplasia.
First author (year) MTR SE 95% LCI 95% UCI
Study design: prospective
0.111 0.118 −0.120 0.342
0.067 0.089 −0.107 0.240
0.048 0.115 −0.178 0.274
0.253 0.168 −0.076 0.581
0.139 0.193 −0.241 0.518
Pooled-MTR 0.097 0.054 −0.009 0.204
Study design: retrospective
0.132 0.145 −0.152 0.416
0.163 0.255 −0.337 0.663
0.145 0.191 −0.228 0.519
0.098 0.128 −0.152 0.347
0.242 0.280 −0.306 0.791
0.072 0.127 −0.176 0.321
0.097 0.162 −0.220 0.414
0.118 0.152 −0.180 0.415
0.268 0.211 −0.146 0.682
0.085 0.095 −0.102 0.271
0.071 0.146 −0.216 0.357
Pooled-MTR 0.110 0.045 0.022 0.199
−0.50 −0.25 0.00 0.25 0.50
−0.50 −0.25 0.00 0.25 0.50
MTR and 95% CI
Mincer et al. (1972)
Gupta et al. (1980)
Lumerman et al. (1995)
Cowan et al. (2001)
Holmstrup et al. (2006)
Hsue et al. (2007)
Ho et al. (2009) 
Arduino et al. (2009)
Bradley et al. (2010)
Warnakulasuriya et al. (2011)
Liu et al. (2011)
Ho et al. (2012)
Zhang et al. (2012)
Sperandio et al. (2013)
Dost et al. (2014)
B ́anóczy and Csiba (1976)
Prospective: I2: 0.0%; Q-value: 1.221, df: 4, and p = 0.875.
Retrospective: I2: 0.0%; Q-value: 1.134, df: 10, and p = 1.000.
Figure 3: Subgroup analysis (D&L fixed effect model): malignant transformation rate, by study design.
four studies from Asia (pooled-MTR: 8.9%, 95% CI: −3.8%
to 21.6%; fixed effect model: 𝐼2 = 0.0%, 𝑄-value: 1.209, and
𝑝 > 0.05) (Figure 4). Severe grade of dysplasia was reported
in twelve studies which were shown to have a higher pooled-
MTR in person year (pooled-MTR: 14.4%, 95% CI: 5.3% to
23.5%; fixed effect model: 𝐼2 = 0.0%,𝑄-value: 10.218, and 𝑝 >
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Table 4: Sensitivity analysis showing MTR in studies using different exclusion criteria.
Number of studies Pooled-MTR∗ LCI UCI 𝑄-stats (𝑝 value) 𝐼2%
All trials 16 10.5% 3.7% 17.3% 1.010 (>0.05) 0.0%
Single- or double-blinded 9 11.4% 1.9% 21.0% 2.389 (>0.05) 0.0%
∗Fixed effect model; LCI: 95% lower confidence interval; UCI: upper confidence interval.
First author (year) MTR SE 95% LCI 95% UCI MTR and 95% CI
Region: Asia
0.067 0.089 −0.107 0.240
0.048 0.115 −0.178 0.274
0.242 0.280 −0.306 0.791
0.268 0.211 −0.146 0.682
Pooled-MTR 0.089 0.065 −0.038 0.216
Region: North America
0.111 0.118 −0.120 0.342
0.163 0.255 −0.337 0.663
0.097 0.162 −0.220 0.414
0.139 0.193 −0.241 0.518
0.085 0.095 −0.102 0.271
0.071 0.146 −0.216 0.357
Pooled-MTR 0.099 0.057 −0.013 0.210
Region: Europe
0.132 0.145 −0.152 0.416
0.145 0.191 −0.228 0.519
0.098 0.128 −0.152 0.347
0.072 0.127 −0.176 0.321
0.118 0.152 −0.180 0.415
0.253 0.168 −0.076 0.581
Pooled-MTR 0.126 0.060 0.008 0.243
−0.50 −0.25 0.00 0.25 0.50
−0.50 −0.25 0.00 0.25 0.50
−0.50 −0.25 0.00 0.25 0.50
Mincer et al. (1972)
Gupta et al. (1980)
Lumerman et al. (1995)
Cowan et al. (2001)
Holmstrup et al. (2006)
Hsue et al. (2007)
Ho et al. (2009) 
Arduino et al. (2009)
Bradley et al. (2010)
Warnakulasuriya et al. (2011)
Liu et al. (2011)
Ho et al. (2012)
Zhang et al. (2012)
Sperandio et al. (2013)
Dost et al. (2014)
B ́anóczy and Csiba (1976)
Asia: I2: 0.0%; Q-value: 1.209, df: 3, and p = 0.751.
North America: I2: 0.0%; Q-value: 0.175, df: 5, and p = 0.999.
Europe: I2: 0.0%; Q-value: 0.815, df: 5, and p = 0.976.
Figure 4: Subgroup analysis (D&L fixed effect model): malignant transformation rate, by region.
0.05) as compared to eleven studies that looked at moderate
dysplasia (pooled-MTR: 9.1%, 95% CI: 1.6% to 16.7%; fixed
effect model: 𝐼2 = 0.0%, 𝑄-value: 2.588, and 𝑝 > 0.05) and
eleven studies that looked at mild dysplasia (pooled-MTR:
6.5%, 95% CI: 0.0% to 13.0%; fixed effect model: 𝐼2 = 0.0%,
𝑄-value: 2.142, and 𝑝 > 0.05) (Figure 5).
No sensitivity analyses were conducted for low versus
high risk of selection bias as no study had high risk (Table 3).
Analysis regarding blinding showed an increase in the MTR
in person years within nine blinded studies (fixed effect
model: pooled-MTR = 11.4%; CI: 1.9% to 21.0%) after exclu-
sion of five nonblinded and two studies that did not report on
blinding (Table 4).
3.4. Risk of Bias across Studies. Funnel plot shows a fairly
symmetrical distribution of the studies across the mean line,
suggesting no strong evidence of publication bias (Figure 6).
4. Discussion
4.1. Summary ofMain Result. The results of themeta-analysis
showed a malignant transformation rate of 10.5% amongst
patients with histologically confirmed oral epithelial dyspla-
sia undergoing long-term follow-up. This was lower than the
previous estimate of 12.1% from themost recentmeta-analysis
paper, published in 2009 [23]. This difference in malignant
transformation rates could be due to the exclusion of studies
8 Journal of Oral Diseases
First author (year) MTR SE 95% LCI 95% UCI MTR and 95% CI
Mild dysplasia
0.077 0.110 −0.140 0.293
0.158 0.251 −0.335 0.650
0.119 0.141 −0.157 0.395
0.030 0.081 −0.129 0.189
0.049 0.115 −0.177 0.275
0.048 0.097 −0.142 0.238
0.185 0.175 −0.159 0.529
0.200 0.149 −0.092 0.492
0.126 0.185 −0.236 0.488
0.039 0.065 −0.088 0.165
0.041 0.111 −0.177 0.258
Pooled-MTR 0.065 0.033 0.000 0.130
Moderate dysplasia
0.070 0.105 −0.136 0.276
0.063 0.088 −0.111 0.236
0.167 0.258 −0.339 0.673
0.077 0.113 −0.145 0.673
0.040 0.094 −0.145 0.225
0.132 0.189 −0.238 0.502
0.157 0.176 −0.187 0.501
0.355 0.199 −0.034 0.744
0.141 0.195 −0.242 0.523
0.101 0.104 −0.103 0.306
0.071 0.146 −0.216 0.357
Pooled-MTR 0.091 0.039 0.016 0.167
Severe dysplasia
0.417 0.257 −0.087 0.921
0.231 0.170 −0.102 0.564
0.167 0.258 −0.339 0.673
0.071 0.109 −0.142 0.285
0.409 0.302 −0.182 1.000
0.329 0.298 −0.255 0.913
0.267 0.229 −0.182 0.715
0.435 0.269 −0.093 0.962
0.550 0.247 −0.065 1.035
0.176 0.218 −0.252 0.605
0.207 0.149 −0.085 0.499
0.018 0.074 −0.127 0.164
Pooled-MTR 0.144 0.046 0.053 0.235
−0.50 −0.25 0.00 0.25 0.50
−0.50 −0.25 0.00 0.25 0.50
−0.50 −0.25 0.00 0.25 0.50
Mincer et al. (1972)
Lumerman et al. (1995)
Lumerman et al. (1995)
Holmstrup et al. (2006)
Arduino et al. (2009)
Holmstrup et al. (2006)
Arduino et al. (2009)
Bradley et al. (2010)
Warnakulasuriya et al. (2011)
Bradley et al. (2010)
Warnakulasuriya et al. (2011)
Liu et al. (2011)
Liu et al. (2011)
Ho et al. (2012)
Ho et al. (2012)
Zhang et al. (2012)
Zhang et al. (2012)
Sperandio et al. (2013)
Sperandio et al. (2013)
Dost et al. (2014)
Dost et al. (2014)
B ́anóczy and Csiba (1976)
B ́anóczy and Csiba (1976)
Mincer et al. (1972)
Lumerman et al. (1995)
Holmstrup et al. (2006)
Arduino et al. (2009)
Bradley et al. (2010)
Warnakulasuriya et al. (2011)
Ho et al. (2012)
Zhang et al. (2012)
Sperandio et al. (2013)
Dost et al. (2014)
B ́anóczy and Csiba (1976)
Mild dysplasia: I2: 0.0%; Q-value: 2.142, df: 10, and p = 0.995.
Moderate dysplasia: I2: 0.0%; Q-value: 2.588, df: 10, and p = 0.990.
Severe dysplasia: I2: 0.0%; Q-value: 10.218, df: 11, and p = 0.511.
Figure 5: Subgroup analysis (D&L fixed effect model): malignant transformation rate, by grade of dysplasia.
that linked oral leukoplakia as a form of oral dysplasia from
this current meta-analysis. However, seven studies [7, 8, 11–
13, 17, 18] from the previous meta-analysis [23] were eligible
in the current meta-analysis.
Our current meta-analysis found that prospective cohort
and studies published in regions with high prevalence of
oral cancer reported higher MTR (Europe > North America
> Asia). These analyses also show that individuals with
severe form of dysplasia have a high rate of malignant
transformation in person years as compared to moderate and
mild form of dysplasia (Severe >Moderate >Mild).
4.2. Applicability of Evidence. The reviewed studies were all
observational cohorts (prospective and retrospective) that
were conducted at hospital and in laboratory based settings
from all parts of the world. The diagnosis and grading of oral
epithelial dysplasia were histologically confirmed across all
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Figure 6: Funnel plot, assessing publication bias.
the studies and excluded oral leukoplakia studies that might
overestimateMTR.The population among all the studies had
similar mean ages with adequate follow-up time and, as most
of the studies were focused at high risk regions for oral cancer,
these review results potentially apply to the majority of the
adults with histologically confirmed oral epithelial dysplasia.
However, it would give us a better picture to generalize these
results even further after examining results from studies from
other regions of the world.
4.3. Added Values of This Study. By combining these 16
studies for the purpose of the current meta-analysis, we have
been able to increase the sample size (3708 participants) and
thus the power to detect the true malignant transformation
rate (MTR) by mean follow-up year. We have summarized
the results of the same number of studies devoted to the same
MTR analysis.The findings from the current study, as a result,
could serve for evidence based medicine issues.
4.4. Strength and Weaknesses. This review and meta-analysis
study was conducted in accordance with the MOOSE guide-
lines [5]. The meta-analysis included studies that only inves-
tigated histologically confirmed oral epithelial dysplasia cases
and their malignant transformation rate, while excluding
the ones that looked at oral leukoplakia, so as to provide a
more reliable histopathologic classification and prevent OED
misclassification.
A limitation of this meta-analysis was that only papers
published in English literature were included. More effort in
identifying the non-English studies is necessary. The assess-
ment of the quality of observational studies was challenging,
as there are no standard tools currently in wide use. To
overcome this problem, we used the tool provided by the
NIH for assessing the risk of bias and quality of the study.
Further, this study did not investigate any of the predictive
risk factors, such as smoking, alcohol use, and site and its
effect on malignant transformation rate.
5. Conclusion
This study shows that oral epithelial dysplasia has a significant
rate of transformation to cancer, which increases significantly
among severe grades of dysplasia.These findings suggest that
developed countries (regions) with higher incidence of oral
cancer may have higher rate of transformation that might be
attributed to other predictive risk factors.
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